Exposed Seronegative: Cellular Immune Responses to SARS-CoV-2 in the Absence of Seroconversion
Overview
Affiliations
The factors determining whether infection will occur following exposure to SARS-CoV-2 remain elusive. Certain SARS-CoV-2-exposed individuals mount a specific T-cell response but fail to seroconvert, representing a population that may provide further clarity on the nature of infection susceptibility and correlates of protection against SARS-CoV-2. Exposed seronegative individuals have been reported in patients exposed to the blood-borne pathogens Human Immunodeficiency virus and Hepatitis C virus and the sexually transmitted viruses Hepatitis B virus and Herpes Simplex virus. By comparing the quality of seronegative T-cell responses to SARS-CoV-2 with seronegative cellular immunity to these highly divergent viruses, common patterns emerge that offer insights on the role of cellular immunity against infection. For both SARS-CoV-2 and Hepatitis C, T-cell responses in exposed seronegatives are consistently higher than in unexposed individuals, but lower than in infected, seropositive patients. Durability of T-cell responses to Hepatitis C is dependent upon repeated exposure to antigen - single exposures do not generate long-lived memory T-cells. Finally, exposure to SARS-CoV-2 induces varying degrees of immune activation, suggesting that exposed seronegative individuals represent points on a spectrum rather than a discrete group. Together, these findings paint a complex landscape of the nature of infection but provide clues as to what may be protective early on in SARS-CoV-2 disease course. Further research on this phenomenon, particularly through cohort studies, is warranted.
Mazzotti L, Borges de Souza P, Azzali I, Angeli D, Nanni O, Sambri V HLA. 2025; 105(1):e70011.
PMID: 39807702 PMC: 11731316. DOI: 10.1111/tan.70011.
Ahmed M, Einhauser S, Peiter C, Senninger A, Baranov O, Eser T iScience. 2024; 27(6):110138.
PMID: 38974469 PMC: 11225850. DOI: 10.1016/j.isci.2024.110138.
Chwa J, Kim M, Lee Y, Cheng W, Shin Y, Jumarang J Viruses. 2024; 16(6).
PMID: 38932145 PMC: 11209246. DOI: 10.3390/v16060852.
Hvidt A, Guo H, Andersen R, Lende S, Vibholm L, Sogaard O BMC Immunol. 2023; 24(1):45.
PMID: 37974069 PMC: 10652616. DOI: 10.1186/s12865-023-00583-y.
Raju Paul S, Scholzen A, Reeves P, Shepard R, Hess J, Dzeng R Front Immunol. 2023; 14:1249581.
PMID: 37885896 PMC: 10598782. DOI: 10.3389/fimmu.2023.1249581.